Search results

The purpose of this paper is to investigate epidemiology and control strategies of the four priority vector-borne diseases (VBDs) in Nepal, i.e. malaria, Kala-azar (visceral leishmaniasis), lymphatic filariasis (LF) and dengue fever/dengue hemorrhagic fever.

The study was a retrospective design to collect data during 1998–2016 from VBDs endemic districts of Nepal. All data were reviewed and epidemiological information of the four VBDs were analyzed.

The number of malaria cases during 1998–2016 of the 13 affected districts was declined from 8,498 to 991 cases with no record of deaths since 2012. The number of cases and deaths in the 12 kala-azar (visceral leishmaniasis) affected districts in 1998 was 1,409 and 42 cases, respectively, but was dramatically decreased in 2016 to 213 and 2 cases, respectively. LF cases of the 61 affected districts in 2011, 2014 and 2016 were 28,855, 30,000 and 33,517 cases, respectively. In total, 25 districts achieved elimination target and the remaining are expected to complete the needful cycles by 2018. Dengue incidence of the 31 affected districts during 2006–2015 was under controlled with reported cases of 642, 356 and 136 cases in 2013, 2014 and 2015, respectively, and only one death in 2015. Implementation of control strategies particularly disease management and community peoples’ awareness significantly reduced the cases and deaths of the target VBDs.

The results of this study clearly suggest that the current control strategies have been worked effectively. However, in particular of the VBDs, health education in communities in the endemic areas should be adopted for better community participation in the context of the primary health care approach and increase the effectiveness of disease control.

VBDs, i.e., malaria, kala-azar (visceral leishmaniasis), LF and dengue fever/dengue hemorrhagic fever, are major causes of morbidity and mortality in the least developed countries which include Nepal. Globalization of travel and trading, unplanned urbanization, environmental and climate change are having a significant impact on disease transmission. Therefore, the Ministry of Health of Nepal had brought some changes in strategies based on activities for disease control, vector control, preventive and preparedness for outbreak response. Consequently, the cases and deaths due to malaria, kala-azar (visceral leishmaniasis), lymphatic filaiasis and dengue fever/dengue hemorrhagic fever have been brought down markedly.

There is growing awareness that global public health problems are so complex, and require such major resources, that neither states nor other stakeholders can tackle them and achieve the millennium development goals (MDGs) on their own. This paper aims to examine the relevance of the MDGs to the pharmaceutical sector and summarizes the industry's contributions to helping achieve the MDGs in the context of its business goals.

The paper reviews the MDGs for which industry has made significant contributions, particularly goal 4: reduce child mortality; goal 5: improve maternal health; goal 6: combat HIV/AIDS, malaria and other diseases; and goal 8: develop a global partnership for development. The paper focuses on two public‐private partnerships (PPPs) in particular – the Merck MECTIZAN^® Donation Program, for the elimination of river blindness as a public health problem, and the African Comprehensive HIV/AIDS Partnerships to address the HIV/AIDS epidemic in Botswana – and outlines some lessons learned. The paper also offers some considerations for PPPs to contribute further to public health and the MDGS in the future.

The pharmaceutical industry has made some major contributions to addressing public health challenges. Along the way, companies such as Merck & Co., Inc. (Whitehouse Station, New Jersey; Merck operates in most countries outside the USA as Merck Sharp & Dohme) have learned useful lessons that can be shared to inform the approach and practices of other PPPs in global health.

Relatively few overviews document the industry's contributions to public health, especially in relation to the MDGs. This paper provides a first step to fill that gap at a time when interest in PPPs is increasing.

This paper aims to provide a comprehensive overview of existing research on stigma in Arab countries.

A rapid review approach was used, leveraging the Scopus database to identify relevant articles. This streamlined method allows for timely assessments of the current state of knowledge, identifies research gaps and is particularly relevant given the social and cultural dynamics in Arab countries.

This study identified a growing interest in stigma-related topics in Arab countries, with a notable increase in the number of publications and citations over the past decade. Research focused on various aspects of stigma, including mental health, HIV, COVID-19 and diverse health conditions, shedding light on the prevalent challenges faced by different populations. Additionally, comparative studies highlighted the influence of culture and gender on the expression of stigma in the region.

To combat stigma in Arab countries, this study suggests the need for culturally sensitive interventions, integration of mental health services into health-care systems and the development of public health campaigns. These measures should be designed to protect vulnerable populations and prioritize educational initiatives for both the younger generation and health-care professionals.

Reducing stigma in Arab countries is crucial for fostering greater social cohesion, equality and overall well-being. The study underscores the importance of collaborations to adapt successful strategies to the unique Arab context.

This paper fills a crucial research gap by investigating stigma in Arab countries, emphasizing the need for culturally sensitive interventions, education integration and international collaboration to combat it effectively.

The purpose of this chapter is to offer reflections on conventional theories concerning causes and determinants of diseases. It also intends to examine both theoretical and empirical bases for adopting an Integrated Social-Ecological Systems (ISES) lens as a tool for understanding complexities related to drivers, determinants and causes of diseases.

We assessed the theoretical underpinnings of a range of historical and contemporary lenses for viewing infectious disease drivers and the implications of their use when used to explain both personal (i.e. individual) and population health. We examined these issues within the empirical context of the City of Dhaka (Bangladesh) by adopting an ISES lens. Within this study an emphasis has been placed on illustrating how feedback loops and non-linearity functions in systems have a direct bearing upon various aspects of infectious disease occurrences.

A brief triumph over microbes during the last century stemmed in part from our improved understanding of disease causation which was built using disciplinary-specific, monocausal approaches to the study of disease emergence. Subsequently, empirical inquiries into the multi-factorial aetiology and the ‘web of causation’ of disease emergence have extended frameworks beyond simplistic, individualistic descriptions of disease causation. Nonetheless, much work is yet to be done to understand the roles of complex, intertwined, multi-level, social-ecological factors in affecting disease occurrence. We argue, a transdisciplinary-oriented, ISES lens is needed to explain the complexities of disease occurrence at various and interacting levels. More theoretical and empirical formulations, with evidence derived from various parts of the world, is also required to further the debate.

Our study advances the theoretical as well as empirical basis for considering an integrated human-nature systems approach to explaining disease occurrence at all levels so that factors at the individual, household/neighbourhood, local, regional and global levels are not treated in isolation.

There is sufficient evidence to prove that the improved health status of a nation’s citizens results in economic growth and development via improved functionality and productivity of labor. It is also commonly accepted that healthcare expenditure significantly influences health status through, for instance, improving life expectancy at birth and reducing morbidity, death, and infant mortality rates. Within healthcare, medicines account for a considerable share of health-related expenditure in both developed and developing countries. Therefore, it seems reasonable to assume that improved access to medicines is likely to contribute not only to the well-being of families and individuals but also to the economic growth and development in all societies. It has been widely advocated that pharmaceutical multinational enterprises (MNEs) can play an important role to address this problem, as they develop and supply a significant proportion of the drugs imported by low- and middle-income countries. This chapter is dedicated to a systematic review of literature in order to identify the strategies implemented by pharmaceutical MNEs to improve access to medicines in the low- and middle-income countries. A total of 76 research articles have been identified, and we have found that the main strategies of pharmaceutical MNEs are related to improving health outcomes through R&D, establishing partnerships for product development, pricing strategies to improve access to medicines, technology transfer, licensing agreements, and nonmarket efforts to improve access to medicines, among other strategies to overcome barriers imposed by intellectual property rights. We have also found that pharmaceutical MNEs’ strategies take place within a complex system and often involve interactions with a wide range of actors, such as international organizations, governments, private not-for-profit sector, universities and research institutes, and generic manufacturers. However, there is still a need for major progress in the field of access to medicines, and pharmaceutical MNEs should be more active in this field in order to avoid potential negative consequences, such as loss of legitimacy and compulsory licensing of their patented medicines.